FBRX
Income statement / Annual
Last year (2025), Forte Biosciences Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Forte Biosciences Inc's net income was -$69.38 M.
See Forte Biosciences Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$18.04 M |
$41.00 K |
$49.00 K |
| Cost of Revenue |
$64.00 K
|
$39.00 K
|
$9.00 K
|
$0.00
|
$36.00 K
|
$54.00 K
|
$11.00 K
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$64.00 K
|
-$39.00 K
|
-$9.00 K
|
$0.00
|
-$36.00 K
|
-$54.00 K
|
-$11.00 K
|
$18.04 M
|
$41.00 K
|
$49.00 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
| Research and Development Expenses |
$58.25 M
|
$21.19 M
|
$21.86 M
|
$5.59 M
|
$13.85 M
|
$9.95 M
|
$2.67 M
|
$50.46 M
|
$29.11 M
|
$27.22 M
|
| General & Administrative Expenses |
$12.41 M
|
$0.00
|
$10.62 M
|
$8.30 M
|
$7.63 M
|
$0.00
|
$0.00
|
$265.68 K
|
$8.56 M
|
$4.52 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
-$9.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$12.54 M
|
-$292.00 K
|
-$255.00 K
|
| Selling, General & Administrative Expenses |
$12.41 M
|
$15.37 M
|
$10.62 M
|
$8.30 M
|
$7.63 M
|
$4.22 M
|
$1.38 M
|
$12.81 M
|
$8.27 M
|
$4.27 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$0.00
|
$17.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$50.00 K
|
| Operating Expenses |
$70.66 M
|
$36.56 M
|
$32.48 M
|
$13.90 M
|
$21.49 M
|
$14.17 M
|
$4.05 M
|
$63.26 M
|
$37.38 M
|
$31.49 M
|
| Cost And Expenses |
$70.66 M
|
$36.60 M
|
$32.49 M
|
$13.90 M
|
$21.49 M
|
$14.23 M
|
$4.06 M
|
$63.89 M
|
$37.67 M
|
$31.74 M
|
| Interest Income |
$2.72 M
|
$1.31 M
|
$1.12 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$595.00 K
|
$0.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$173.38 K
|
$1.93 M
|
-$1.84 M
|
| Depreciation & Amortization |
$64.00 K
|
$39.00 K
|
$9.00 K
|
$36.00 K
|
$36.00 K
|
$54.00 K
|
$11.00 K
|
$625.00 K
|
$292.00 K
|
$255.00 K
|
| EBITDA |
-$70.59 M |
-$35.44 M |
-$32.48 M |
-$13.86 M |
-$21.45 M |
-$46.43 M |
-$4.06 M |
-$43.69 M |
-$36.71 M |
-$31.17 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-2.42
|
-895.24
|
-636.14
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-2.54
|
-917.78
|
-646.76
|
| Total Other Income/Expenses Net |
$2.32 M
|
$1.12 M
|
$1.01 M
|
$17.00 K
|
-$222.00 K
|
-$32.26 M
|
-$5.00 K
|
-$1.40 M
|
-$1.30 M
|
-$1.79 M
|
| Income Before Tax |
-$68.34 M
|
-$35.48 M
|
-$31.48 M
|
-$13.88 M
|
-$21.71 M
|
-$46.49 M
|
-$4.07 M
|
-$47.26 M
|
-$38.93 M
|
-$33.48 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-2.62
|
-949.49
|
-683.22
|
| Income Tax Expense |
$1.04 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.70 M
|
$0.00
|
$0.00
|
| Net Income |
-$69.38 M
|
-$35.48 M
|
-$31.48 M
|
-$13.86 M
|
-$21.71 M
|
-$46.49 M
|
-$4.07 M
|
-$48.96 M
|
-$38.93 M
|
-$33.48 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-2.71
|
-949.49
|
-683.22
|
| EPS |
-4.71 |
-12.17 |
-24.92 |
-19.96 |
-38.8535 |
-157.9272 |
-48.2512 |
-915.18 |
-997.5 |
-634.7962 |
| EPS Diluted |
-4.71 |
-12.17 |
-24.92 |
-19.96 |
-38.8535 |
-157.9272 |
-48.2512 |
-915.18 |
-997.5 |
-634.7962 |
| Weighted Average Shares Out |
$147.18 M
|
$2.92 M
|
$1.26 M
|
$695.34 K
|
$558.71 K
|
$294.36 K
|
$84.33 K
|
$53.49 K
|
$38.95 K
|
$52.74 K
|
| Weighted Average Shares Out Diluted |
$147.18 M
|
$2.92 M
|
$1.26 M
|
$695.34 K
|
$558.71 K
|
$294.36 K
|
$84.33 K
|
$53.49 K
|
$38.95 K
|
$52.74 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
